HAMBURG, Germany, July 9, 2013 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN:DE0005664809) today announced that Evotec and Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company (NYSE:DOW), have entered into a research collaboration with the objective of leveraging Evotec's advanced chemical proteomics services to support compounds in development at Dow AgroSciences. To this end, Evotec will perform quantitative chemical proteomics services (Cellular Target Profiling ®) to de-convolute phenotypic screening results obtained by Dow. Dr Mario Polywka, Chief Operating Officer of Evotec, commented : "We look forward to working with Dow AgroSciences on this project. This collaboration highlights the broad applicability of Evotec's industry leading chemical proteomics platform to determine cellular target affinities and mechanisms of action on a proteome wide level and in a native context." Dr William Kleschick, Discovery Global Leader of Dow AgroSciences, added : "Dow AgroSciences is pleased to announce this new partnership with Evotec, an innovative leader in advanced chemical proteomics. This collaboration enhances Discovery's technology tool-box to accelerate our efforts to deliver novel solutions to our customers around the world." No financial details are disclosed. ABOUT EVOTEC AG Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca and Ono Pharmaceutical. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes, with Janssen Pharmaceuticals in the field of depression and with Roche in the field of Alzheimer's disease. For additional information please go to www.evotec.com . ABOUT DOW AGROSCIENCES Dow AgroSciences, based in Indianapolis, Indiana, USA, develops leading-edge crop protection and plant biotechnology solutions to meet the challenges of the growing world. Dow AgroSciences is a wholly owned subsidiary of The Dow Chemical Company and had annual global sales of $6.4 billion in 2012. Learn more at www.dowagro.com . Follow Dow AgroSciences on Facebook and YouTube or subscribe to our News Release RSS Feed. FORWARD LOOKING STATEMENTS — Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
CONTACT: Gabriele Hansen Head of Corporate Communications +49.(0)40.560 81-255 +49.(0)40.560 81-222 Fax email@example.com Evotec AG Manfred Eigen Campus Essener Bogen 7 22419 Hamburg (Germany)